Evidence map›Paper›PMID 39031010›Full record

ArticleCancer medicine2024

Select gene mutations associated with survival outcomes in ER-positive ERBB2-negative early-stage invasive breast cancer: A single-institutional tissue bank study.

Victor C Kok, To-Yu Huang, Yi-Chiung Hsu, Yuan-Ching Chang, Po-Sheng Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Victor C KokDivision of Medical Oncology, Kuang Tien General Hospital Cancer Center, Taichung, Taiwan.ORCID 0000-0003-3440-8154
To-Yu HuangDepartment of Medical Research, MacKay Memorial Hospital, New Taipei, Taiwan.ORCID 0009-0008-6870-8749
Yi-Chiung HsuDepartment of Biomedical Sciences and Engineering, National Central University, Taoyuan, Taiwan.ORCID 0000-0002-8712-8714
Yuan-Ching ChangDepartment of General Surgery, MacKay Memorial Hospital, Taipei, Taiwan.
Po-Sheng YangDepartment of General Surgery, MacKay Memorial Hospital, Taipei, Taiwan.ORCID 0000-0002-6226-2618

Funding

MacKay Memorial Hospital MMH-106-73MacKay Memorial Hospital MMH-107-49National Science and Technology Council NSTC 112-2314-B-008-003National Science and Technology Council NSTC 112-2321-B-195-001
6 · The paper itself

Abstract

introductionThe prognostic capability of targeted sequencing of primary tumors in patients with estrogen receptor-positive, human epidermal growth factor receptor-2-negative early-stage invasive breast cancer (EBC) in a real-world setting is uncertain. Therefore, we aimed to determine the correlation between a 22-gene mutational profile and long-term survival outcomes in patients with ER+/ERBB2- EBC. PATIENTS AND

methodsA total of 73 women diagnosed with ER+/ERBB2- EBC between January 10, 2004, and June 2, 2008, were followed up until December 31, 2022. Univariate and multivariate Cox models were constructed to plot the relapse-free survival (RFS) and overall survival (OS). The log-rank test derived p-value was obtained. For external validation, we performed a survival analysis of 1163 comparable patients retrieved from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset.

resultsAt follow-up, 16 (21.9%) patients had relapsed, while 21 (nearly 29%) harbored mutant genes. Thirty-three missense mutations were detected in 14 genes. The median ages were 51 and 46 years in patients with and without mutations, respectively. Patients with any mutation had a 1.85-fold higher risk of relapse (hazard ratio [HR]: 1.85, 95% confidence interval [CI]: 0.60-5.69) compared to those without any mutation. Patients who harbored any of the six genes (MAP2K4, FGFR3, APC, KIT, RB1, and PTEN) had a nearly 6-fold increase in the risk of relapse (HR: 5.82, 95% CI: 1.31-18.56; p = 0.0069). Multivariate Cox models revealed that the adjusted HR for RFS and OS were 6.67 (95% CI: 1.32-27.57) and 8.31 (p = 0.0443), respectively. METABRIC analysis also demonstrated a trend to significantly worse RFS (p = 0.0576) in the subcohort grouped by having a mutation in any of the six genes.

conclusionsOur single-institution tissue bank study of Taiwanese women with ER+/ERBB2- EBC suggests that a novel combination of six gene mutations might have prognostic capability for survival outcomes.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesMutationReceptors, EstrogenAdultAgedBiomarkers, TumorFemaleHumansMiddle AgedNeoplasm InvasivenessNeoplasm StagingPrognosisBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenER+/HER2‐multigene mutational panelprognosticationrelapse‐free survivaltargeted sequencingtissue bank

Identifiers

PMID39031010
PMCPMC11258552

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.